Abstract:ABSTRACT Background CRISPR-Cas9-based technologies have revolutionized experimental manipulation of mammalian genomes. None-the-less, limitations of the delivery and efficacy of these technologies restrict their application in primary cells. Aims To create an optimized protocol for penetrant, reproducible, and fast targeted insertiondeletion mutation (indel) formation in cell cultures derived from primary cells, using patient-derived glioblastoma (GBM) stem-like cells (GSCs) and human neural stem/progenitor cells (NSCs) for proof-of-concept experiments. Methods We employed transient nucleofection of Cas9:sgRNA ribonucleoprotein complexes using chemically synthesized 2’-O-methyl 3’phosphorothioate-modified sgRNAs and purified Cas9 protein. Indel frequency and size distribution were measured via computational deconvolution of Sanger sequencing trace data. Western blotting was used to evaluate protein loss. RNA-seq in edited NSCs was used to assess gene expression changes resulting from knockout of tumor suppressors commonly altered in GBM. Results We found that with this optimized technique, we can routinely achieve >90% indel formation in only 3 days, without the need to create clonal lines for simple loss-of-function experiments. We observed near-total protein loss of target genes in cell pools. Additionally, we found that this approach allows for the creation of targeted genomic deletions. We also demonstrated the utility of this method for quickly creating a series of gene knockouts that allow for the study of oncogenic activities. Conclusion Our data suggest that this relatively simple method can be used for highly efficient and fast gene knockout, as well as for targeted genomic deletions, even in hyperdiploid cells (such as GSCs). This represents an extremely useful tool for the cancer research community when wishing to inactivate not only coding genes, but also non-coding RNAs, UTRs, enhancers, and promoters. This method can be readily applied to diverse cell types by varying the nucleofection conditions.

Efficient engineering of human and mouse primary cells using peptide-assisted genome editing

CRISPR-Cas12a System With Synergistic Phage Recombination Proteins for Multiplex Precision Editing in Human Cells

An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing

Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes

Chapter Two - Expression and purification of cell-penetrating Cas9 and Cas12a enzymes for peptide-assisted genome editing

Advanced Peptide Nanoparticles Enable Robust and Efficient delivery of gene editors across cell types

Peptide-enabled ribonucleoprotein delivery for CRISPR engineering (PERC) in primary human immune cells and hematopoietic stem cells

Small Molecules Promote CRISPR-Cpf1-mediated Genome Editing in Human Pluripotent Stem Cells

A simple and highly efficient method for multi-allelic CRISPR-Cas9 editing in primary cell cultures

Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis

Efficient Generation and Correction of Mutations in Human iPS Cells Utilizing mRNAs of CRISPR Base Editors and Prime Editors

Engineering CRISPR/Cpf1 with tRNA promotes genome editing capability in mammalian systems

Precision genome editing using cytosine and adenine base editors in mammalian cells

Fast-Track and Integration-Free Method of Genome Editing by CRISPR/Cas9 in Murine Pluripotent Stem Cells

CRISPR-Cas12a for Highly Efficient and Marker-Free Targeted Integration in Human Pluripotent Stem Cells

An in situ cut-and-paste genome editing platform mediated by CRISPR/Cas9 or Cas12a

Efficient Genome Editing of Mice by CRISPR Electroporation of Zygotes

Efficient gene knockout in primary human and murine myeloid cells by non-viral delivery of CRISPR-Cas9

CRISPR/Cas9‐Directed Genome Editing of Cultured Cells

Highly efficient CRISPR-mediated genome editing through microfluidic droplet cell mechanoporation

Computationally guided high-throughput engineering of an anti-CRISPR protein for precise genome editing in human cells